High-dose argatroban for treatment of heparin-induced thrombocytopenia with thrombosis: A case report and review of laboratory considerations

American Journal of Health-System Pharmacy

Volumn 69, Issue 6, 2012, Pages 490-495

  Hellwig, Thaddaus R ^a,b   Peitz, Gregory J ^c,d   Gulseth, Michael P ^e,f  

^a SOUTH DAKOTA STATE UNIVERSITY   (United States)

^b UNIVERSITY OF SOUTH DAKOTA   (United States)

^c UNIVERSITY OF NEBRASKA MEDICAL CENTER   (United States)

^d UNIVERSITY OF NEBRASKA MEDICAL CENTER   (United States)

^e USD Medical Center   (United States)

^f SDSU   (United States)

Author keywords

Anticoagulants; Argatroban; Blood levels; Coronary artery bypass; Dosage; Heparin; International normalized ratio; Platelet aggregation inhibitors; Thrombocytopenia; Toxicity; Venous thrombosis

Indexed keywords

ACETYLSALICYLIC ACID; ARGATROBAN; CLOPIDOGREL; COD LIVER OIL; CYANOCOBALAMIN; EPTIFIBATIDE; EXENDIN 4; FISH OIL; FOLIC ACID; GLIBENCLAMIDE; GLUCOSAMINE; GLYCERYL TRINITRATE; HEPARIN; ISOSORBIDE MONONITRATE; METFORMIN; METOPROLOL SUCCINATE; PYRIDOXINE; TICLOPIDINE; UBIQUINONE;

ACUTE CORONARY SYNDROME; ADULT; ALLERGY; ARTICLE; BEDTIME DOSAGE; CASE REPORT; CORONARY ARTERY BYPASS GRAFT; DEEP VEIN THROMBOSIS; DRUG DOSE INCREASE; DRUG MEGADOSE; DRUG MONITORING; EVENING DOSAGE; FEMALE; HEPARIN INDUCED THROMBOCYTOPENIA; HEPARINIZATION; HUMAN; INTERNATIONAL NORMALIZED RATIO; MEDICAL HISTORY; MORNING DOSAGE; PARTIAL THROMBOPLASTIN TIME; PRIORITY JOURNAL; RASH; ST SEGMENT ELEVATION MYOCARDIAL INFARCTION; THORAX PAIN;

EID: 84858990180     PISSN: 10792082     EISSN: 15352900     Source Type: Journal    
DOI: 10.2146/ajhp110147     Document Type: Article

References (21)

1. Argatroban package insert. Research Triangle Park, NC: GlaxoSmithKline; 2009 Mar.
2. Warkentin TE. Heparin-induced thrombocytopenia: pathogenesis and management. Br J Haematol. 2003; 121:535-55. (Pubitemid 36645375)
3. Cannon CP, Maraganore JM, Loscalzo J et al. Anticoagulant effects of Hirulog, a novel thrombin inhibitor, in patients with coronary artery disease. Am J Cardiol. 1993; 71:778-82. (Pubitemid 23096690)
4. Swan SK, Hursting MJ. The pharmacokinetics and pharmacodynamics of argatroban: effects of age, gender, and hepatic or renal dysfunction. Pharmacotherapy. 2000; 20:318-29. (Pubitemid 30140749)
5. Nowak G. Clinical monitoring of hirudin and direct thrombin inhibitors. Semin Thromb Hemost. 2001; 27:537-41. (Pubitemid 32989380)
6. Gosselin RC, King JH, Janatpour KA et al. Comparing direct thrombin inhibitors using aPTT, ecarin clotting times, and thrombin inhibitor management testing. Ann Pharmacother. 2004; 38:1383-8. (Pubitemid 39100188)
7. Love JE, Ferrell C, Chandler WL. Monitoring direct thrombin inhibitors with a plasma diluted thrombin time. Thromb Haemost. 2007; 98:234-42.
8. Siegmund R, Boer K, Poeschel K et al. Comparison of the ecarin chromogenic assay and different aPTT assays for the measurement of argatroban concentrations in plasma from healthy individuals and from coagulation factor deficient patients. Thromb Res. 2008; 123:159-65.
9. Lewis BE, Wallis DE, Berkowitz SD et al. Argatroban anticoagulant therapy in patients with heparin-induced thrombocytopenia. Circulation. 2001; 103:1838-43. (Pubitemid 32328395)
10. Lewis BE, Wallis DE, Leya F. Argatroban anticoagulation in patients with heparininduced thrombocytopenia. Arch Intern Med. 2003; 163:1849-56. (Pubitemid 36960936)
11. Verme-Gibboney CN, Hursting MJ. Argatroban dosing in patients with heparin-induced thrombocytopenia. Ann Pharmacother. 2003; 37:970-5. (Pubitemid 36875223)
12. Fenyvesi T, Jorg I, Harenberg J. Monitoring of anticoagulant effects of direct thrombin inhibitors. Sem Thromb Hemost. 2002; 28:361-8. (Pubitemid 34971923)
13. Hafner G, Roser M, Nauck M. Methods for the monitoring of direct thrombin inhibitors. Semin Thromb Hemost. 2002;28:425-30. (Pubitemid 35217487)
14. Lange U, Nowak G, Bucha E. Ecarin chromogenic assay-a new method for quantitative determination of direct thrombin inhibitors like hirudin. Pathophysiol Haemost Thromb. 2003/2004; 33:184-91. (Pubitemid 39664136)
15. Koster A, Hansen R, Kuppe H et al. Recombinant hirudin as an alternative for anticoagulation during cardiopulmonary bypass in patients with heparin-induced thrombocytopenia type II; a 1-year experience in 57 patients. J Cardiothorac Vasc Anesth. 2000; 14:243-8. (Pubitemid 30415918)
16. Fenyvesi T, Harenberg J, Weiss C et al. Comparison of two different ecarin clotting time methods. J Thromb Thrombolysis. 2005; 20:51-6. (Pubitemid 41300623)
17. Van Ryn J, Stangier J, Haertter S et al. Dabigatran etexilate-a novel, reversible, oral direct thrombin inhibitor: interpretation of coagulation assays and reversal of anticoagulant activity. Thromb Haemost. 2010; 103:1116-27.
18. Reid TJ III, Alving BM. A quantitative thrombin time for determining levels of hirudin and Hirulog. Thromb Haemost. 1993; 70:608-16. (Pubitemid 23310566)
19. Nowak G, Bucha E. Quantitative determination of hirudin in blood and body fluids. Semin Thromb Hemost. 1996;22:197-202. (Pubitemid 26239913)
20. Hursting MJ, Sehnder JL, Joffrion JL et al. The International Normalized Ratio during concurrent warfarin and argatroban anticoagulation: differential contributions of each agent and effects of the choice of thromboplastin used. Clin Chem. 1999; 45:409-12. (Pubitemid 29114179)
21. Sheth SB, DiCicco RA, Hersting MJ et al. Interpreting the International Normalized Ratio (INR) in individuals receiving argatroban and warfarin. Thromb Haemost. 2001; 85:435-40. (Pubitemid 32233014)